EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer [2] (multiple letters)

JIN-YUAN SHIHGow C.-H.PAN-CHYR YANG2020-12-022020-12-0220050028-4793https://www.scopus.com/inward/record.uri?eid=2-s2.0-22044454824&doi=10.1056%2fNEJM200507143530217&partnerID=40&md5=b17a1dbab8111aeb06bdc9a16914f581https://scholars.lib.ntu.edu.tw/handle/123456789/523852[SDGs]SDG3cisplatin; epidermal growth factor receptor; gefitinib; gemcitabine; antineoplastic agent; gefitinib; protein kinase inhibitor; quinazoline derivative; adult; anamnesis; brain tumor; cancer radiotherapy; case report; clinical feature; female; gene mutation; human; laboratory test; letter; lung adenocarcinoma; lung non small cell cancer; priority journal; radiosurgery; stereotaxic surgery; drug resistance; genetics; lung non small cell cancer; lung tumor; middle aged; point mutation; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, Epidermal Growth FactorEGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer [2] (multiple letters)letter10.1056/NEJM200507143530217160148932-s2.0-22044454824